Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LALP Cream
- Development stage
- Phase 4
- Lead developer
- Andros Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
LALP Cream is a topical anesthetic combination product developed by Andros Pharmaceuticals. It contains the amide-type local anesthetics lidocaine and prilocaine. The mechanism of action involves the stabilization of neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses, specifically through the blockade of voltage-gated sodium channels. This results in local anesthesia at the site of application. LALP Cream is approved for topical anesthesia on intact skin and for minor superficial cosmetic procedures.
- Brand names
- LALP Cream
- Other names
- lidocaine + prilocaine cream
02
Targets
SCN9A (Sodium channel protein type 9 subunit alpha)SCN5A (Sodium channel protein type 5 subunit alpha)
Beyond the preview
Go deeper on LALP Cream.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LALP Cream.